

AD _____

Award Number: W81XWH-04-1-0733

TITLE: Antibody-NKG2D Ligand (Rae-1Beta) Fusion Protein for Breast Cancer
Therapy

PRINCIPAL INVESTIGATOR: Seung-Uon Shin, Ph.D.

CONTRACTING ORGANIZATION: University of Miami
Miami, FL 33124

REPORT DATE: August 2005

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20060503122

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-08-2005		2. REPORT TYPE Final		3. DATES COVERED (From - To) 1 Aug 2004 – 31 Jul 2005	
4. TITLE AND SUBTITLE Antibody-NKG2D Ligand (Rae-1Beta) Fusion Protein for Breast Cancer Therapy				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0733	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Seung-Uon Shin, Ph.D. E-mail: mvalero@med.miami.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Miami Miami, FL 33124				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Antibody-NKG2D ligand fusion protein targeted against the breast tumor antigen HER2. Using murine breast tumors designed to express the HER2 target antigen and the murine NKG2D ligand Rae-1 β , we constructed an anti-HER2 IgG3-CH3-Rae-1 β fusion protein by genetically fusing Rae-1 β at the 3' end of CH3 domain of anti-HER2 IgG3 antibody. The purified Rae-1_ fusion proteins demonstrated ability to bind antigen on tumor cells and NKG2D on NK cells. The antibody-Rae-1_ fusion proteins showed increased cytotoxic activity directed against tumor targets.					
15. SUBJECT TERMS Breast, cancer, therapy, fusion protein					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	17	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusions.....	10
References.....	10
Appendices.....	11

ANTIBODY-NKG2D LIGAND (RAE-1BETA) FUSION PROTEIN FOR BREAST CANCER THERAPY

INTRODUCTION

NKG2D ligands are inducible stress response molecules expressed on virally infected and transformed cells.¹ NKG2D ligands activate the NKG2D receptor, a C type lectin-like receptor expressed on effector cells belonging to the innate and adaptive immune systems, and offer an effective link between innate and adaptive immunity necessary to mount potent anti-tumor response.² Over-expression of NKG2D ligands has led to tumor regression in multiple murine tumor models.^{3,4} In contrast to observations derived from murine tumor models, the wide spread expression of these ligands on many human cancers does not generate the anticipated tumor-specific innate or adaptive response seen in mouse tumor models. One explanation for this is the shedding of these ligands into the blood stream and down-regulation of the NKG2D receptor on effector cells. This has the effect of both reducing the surface expression of these ligands on tumor cells while blunting the effectiveness of the receptor itself. Over-expression of NKG2D ligands on tumor cells effectively restores the balance of NK cell activation status in favor of stimulatory signals, provides a potent costimulatory signal to CD8⁺ T cells and can stimulate an effective anti-tumor response. Since most women who succumb to breast cancer harbor metastatic disease, direct transduction strategies effectively employed in murine experimental models to express NKG2D ligands will not be practical.

Our proposal seeks to combine NKG2D ligand, Rae-1 β , with the targeting specificity of an anti-tumor antibody by producing antibody-Rae-1 β fusion protein specific for the tumor antigen HER2.⁵ The proposal wishes to employ the targeting flexibility of antibodies to direct localization of Rae-1 β to the tumor site. We hypothesize that anti-HER2 antibody homing to HER2-positive tumor cells will deliver the NKG2D ligand, Rae-1 β , to tumor cells. Local delivery of NKG2D ligand will effectively re-target NK cell cytotoxicity to tumor cells, leading to an enhanced innate response and priming of an adaptive response mediated by CD8⁺ T cells with anti-tumor specificity.

The objective of this proposal is to develop and test antibody fusion proteins directed against known tumor associated antigens, e.g. HER2, fused to the NKG2D ligand, Rae-1 β , of NK cells. I. Generation of an antibody-Rae-1 β fusion protein. II. Investigation of the immune properties of anti-HER2 antibody-Rae-1 β fusion protein *in vitro* and *in vivo*. III. Study of the antibody-Rae-1 β fusion protein *in vivo* for ability to inhibit tumor growth and/or cause tumor regression in syngeneic animal tumor models.

BODY

Specific Aim I: Generation of an antibody-Rae-1 β fusion protein.

- Task 1.* Construction and expression of anti-HER2 IgG3-C_H3-Rae-1 β fusion protein (Months 1-2).
 - a. Construct anti-HER2 antibody-Rae-1 β fusion gene.
 - b. Express anti-HER2 antibody-Rae-1 β fusion gene.
- Task 2.* Production of anti-HER2 IgG3-C_H3-Rae-1 β (Months 3-6).
 - a. Produce anti-HER2 antibody-Rae-1 β fusion protein in milligram quantities.

- b. Generate a murine mammary tumor cell EMT6-HER2 expressing Rae-1 β (EMT6-HER2-Rae-1 β).

Construction and purification of anti-HER2 IgG3-Rae-1 β fusion proteins

We describe the construction and characterization of the Rae-1 β fusion antibodies in which the extracellular domain without GPI linkage region of the Rae-1 β molecule was fused by genetic engineering to the carboxy terminus of the heavy chain of an anti-HER2 IgG3 antibody. We opted to use the IgG3 backbone for the antibody molecule, since the extended hinge region of

IgG3 would be expected to provide greater flexibility in folding to accommodate the presence of Rae-1 β in the fusion antibody. IgG3 also exhibits Fc-mediated functions, such as complement activation and Fc γ binding. We chose the Rae-1 β NKG2D ligand because NKG2D ligands overexpressed on tumor cells activate both the innate and adaptive arms of the immune responses.

The expression vectors for the human IgG3 heavy and κ light chains were previously constructed in the laboratory. To construct a fusion antibody between anti-HER2 IgG3 and Rae-1 β , the extracellular domain of Rae-1 β was cloned at the 3' end of the heavy chain constant region of anti-HER2 IgG3. Anti-HER2 IgG3-hinge-Rae-1 β (H-Rae-1 β) and anti-HER2 IgG3-C_{H3}-Rae-1 β (C_{H3}-Rae-1 β) fusion proteins have been generated to produce a more effective form of




Fig. 1. Schematic diagram of the proposed anti-HER2 IgG3-Rae-1 β fusion proteins.




Fig. 2. Immunoprecipitation and SDS-PAGE analysis of anti-HER2 IgG3-Rae-1 β fusion protein. The secreted IgG3-C_{H3}-Rae-1 β fusion proteins biosynthetically labeled with [³⁵S] methionine was immunoprecipitated with Protein A and analyzed under non-reducing (A) and reducing (B) conditions. Rae-1 β fusion proteins purified by affinity chromatography were analyzed under non-reducing conditions (C). Control anti-HER2 IgG3 (α HER2 IgG3) is included for comparison.

NKG2D ligand, Rae-1 β , and to explore the possibility the antibody-Rae-1 β fusion protein would target tumor expressing HER2 while retaining NK cell activating activity (Fig. 1). The anti-HER2 IgG3-Rae-1 β genes were constructed and transfected into the murine P3X63Ag8.653

myeloma cell line. The anti-HER2 IgG3-Rae-1 β fusion protein was purified using a Protein A column. An anti-HER2 IgG3-Rae-1 β fusion protein of the expected molecular weight was secreted as the fully assembled H₂L₂ form (Fig. 2).

Specific Aim II: Investigation of the immune properties of anti-HER2 antibody-Rae-1 β fusion protein *in vitro* and *in vivo*.

Task 3. Determination of tumor targeting ability and tissue biolocalization of Rae-1 β fusion protein (Months 4-5).

- Binding ability of anti-HER2 antibody-Rae-1 β fusion protein to EMT6-HER2 tumor cells.
- Binding ability of anti-HER2 antibody-Rae-1 β fusion protein to NK cells.
- Biodistribution and biolocalization of antibody-Rae-1 β fusion protein in tumor bearing mouse.

Task 4. Analysis of biological functions of Rae-1 β fusion protein *in vitro* (Months 6-7).

- Determine *in vitro* cytotoxicity of syngeneic NK cells to EMT6-HER2-Rae-1 β .
- Determine *in vitro* cytotoxicity of syngeneic NK cells to either EMT6-HER2 with/without treatment of Rae-1 β fusion protein.

Antigen binding ability of anti-HER2 IgG3-Rae-1 β fusion proteins

Whether anti-HER2 IgG3-Rae-1 β fusion proteins also retained the specific binding ability to HER2 antigens has been examined with tumor cell line expressing HER2 (such as EMT6-HER2, MC38-HER2, or CT26-HER2). Anti-HER2 antibody-Rae-1 β fusion proteins have been tested for binding to murine tumor cell lines using anti-human IgG or anti-Rae-1 β using flow cytometry (Fig.3). Bound anti-HER2 IgG3-Rae-1 β fusion proteins to HER2 have been detected by anti-murine Rae-1 β antibody conjugated with FITC. Both C_H3-Rae-1 β and H-Rae-1 β have




Fig. 3. Binding ability of anti-HER2 IgG3-Rae-1 β fusion proteins to HER2 antigen. Both C_H3-Rae-1 β (filled with red color) and H-Rae-1 β (blue colored line) have been investigated to recognize HER2, but anti-HER2 IgG3 (green colored line) and isotype control (filled with purple color) did not have been detected.

recognized HER2, but anti-HER2 IgG3 and isotype control (anti-Dansyl IgG3) did not have been detected.

To investigate binding ability of the Rae-1 β moiety in fusion proteins to NKG2D receptor using flow cytometry, anti-HER2 antibody-Rae-1 β fusion proteins have been tested for binding to NK cells freshly isolated from C57BL6 or KY-2 cells (murine NK cell line) which express NKG2D (Fig. 4). Bound anti-HER2 IgG3-Rae-1 β fusion proteins to NKG2D have been detected by anti-human IgG conjugated with FITC. Anti-HER2 IgG3-C_H3-Rae-1 β showed stronger binding ability than anti-HER2 IgG3-H-Rae-1 β on both NK cells. It might be the result of conformational difference between C_H3-Rae-1 β and H-Rae-1 β , and/or due to lack of Fc region in H-Rae-1 β the detection antibody, anti-human IgG-FITC, might recognize H-Rae-1 β less efficiently than C_H3-Rae-1 β . However the control antibodies, anti-dansyl IgG3 and anti-HER2 IgG3, did not show any binding to NK cells. Bound anti-HER2 IgG3-Rae-1 β fusion proteins to HER2 have been detected by anti-murine Rae-1 β antibody conjugated with FITC. C_H3-Rae-1 β and H-Rae-1 β showed equivalent binding ability to tumor cells expressing HER2, while the control antibodies were not detected with anti-Rae-1 β antibody-FITC.

These results demonstrate the anti-HER2 IgG3-Rae-1 β fusion proteins will bind tumor cells and Rae-1 β fusion proteins will bind NKG2D on NK cells through Rae-1 β moiety. The NKG2D:Rae-1 β interaction may stimulate NK cells and will cause tumor lysis by secreted perforin or granzyme B from the activated NK cells.




Fig. 4. Binding ability of anti-HER2 IgG3-Rae-1 β fusion proteins to NKG2D. The Rae-1 β moiety of anti-HER2 antibody-Rae-1 β fusion proteins has been tested for binding to NKG2D on freshly isolated NK cells or murine NK cell line KY-2 cells. Both C_H3-Rae-1 β (filled with red color) and H-Rae-1 β (blue colored line) have been detected through the Rae-1 β moiety, but anti-HER2 IgG3 (green colored line) and isotype control (filled with purple color) did not have been detected through the Rae-1 β moiety.

Enhanced perforin production in KY-2 with anti-HER2 IgG3-Rae-1 β fusion protein.

To evaluate the capacity of anti-HER2 IgG3-Rae-1 β fusion protein to stimulate expression of perforin in NK cells, murine NK KY-2 cells activated with IL-2 (100U) have been stimulated in the presence of anti-HER2 IgG3-C_H3-Rae-1 β fusion protein at the various concentrations (0.1 μ g, 0.5 μ g, or 2 μ g) and controls: anti-HER2 IgG3 (2 μ g) and isotype control (2 μ g). Anti-HER2 IgG3-C_H3-Rae-1 β fusion protein promote perforin expression in KY-2 cells in a dose-dependent manner (Fig.5). This result confirmed that the Rae-1 β moiety of anti-HER2 IgG3-C_H3-Rae-1 β fusion protein is functional.

Intracellular Expression of Perforin in IL-2 Activated KY-2 (murine NK Cell)




Fig. 5. Anti-HER2 IgG3-Rae-1β fusion protein-mediated enhancement of perforin production in KY-2 NK cells. Histograms demonstrate intracellular perforin expression of IL2 (100U)-stimulated KY-2 cell cultured in the presence of anti-HER2 IgG3-C_H3-Rae-1β fusion protein at the various concentrations (0.1 µg: filled with blue color, 0.5 µg: filled with orange color, 2 µg: filled with red color), anti-HER2 IgG3 (2 µg: blue colored line), and isotype control (2 µg: black colored line).

Augmented tumor-directed NK cell-mediated cytotoxicity by anti-HER2 IgG3-Rae-1β fusion protein.

To determine whether anti-HER2 IgG3-Rae-1β fusion proteins enhance the tumoricidal activity of NK cells, freshly isolated NK cells were cultured in the presence of anti-HER2 IgG3-Rae-1β fusion proteins (10 µg/well), anti-HER2 IgG3 (10 µg/well), or control anti-dansyl IgG3 (10 µg/well). After two days of stimulation, cytotoxic potential of NK cells toward the tumor cell line, MC38 expressing HER2 antigens (MC38-HER2), was evaluated in a 5-hr ⁵¹Cr release assay (Fig. 6). The NK cell-mediated cytotoxicities have been done with EMT6-HER2 and CT26-HER2, but the results have been shown similar. Thus, the representative NK cytotoxicity has been presented.

Anti-HER2 IgG3 exhibited little tumor-directed cytotoxicity (20-40%) by NK cells, while anti-dansyl IgG3 did not show cytotoxicity (15-20%), (Fig. 6). Interestingly, whereas the H-Rae-1β fusion protein exhibited only little improvement of tumor-directed cytotoxicity (20-40%) by NK cells, the C_H3-Rae-1β fusion markedly enhanced NK cell-mediated killing activity (50-97%), (Fig. 6). The cytotoxic activity of the H-Rae-1β fusion protein was less potent than the C_H3-Rae-1β fusion protein perhaps due to the absence of an Fc region. These data illustrate that




Fig 6. Enhancement of tumor-directed NK cell-mediated cytotoxicity by anti-HER2 IgG3-Rae-1β fusion protein. Freshly isolated NK cells were stimulated in the presence of anti-HER2 IgG3-Rae-1β fusion proteins (10 µg/well, C_H3-Rae-1β; filled with red color, H-Rae-1β; filled with green color), anti-HER2 IgG3 (10 µg/well, filled with purple color), or control anti-dansyl IgG3 (10 µg/well, black line). After 2 days, NK were cocultured in round-bottom 96-well plates with the ⁵¹Cr-labeled tumor cell lines MC38-HER2 at different E:T ratios. After 5 h of incubation, chromium release was measured. The results of three different donors are presented as mean ± SE of triplicate wells.

both the Rae-1β domain and Fc region of the fusion antibody play important roles in tumor-directed cytotoxicity mediated by NK cells.

Specific Aim III: Study of the antibody-Rae-1 β fusion protein *in vivo* for ability to inhibit tumor growth and/or cause tumor regression in syngeneic animal tumor models.

Task 5. In vivo mechanistic investigation with anti-HER2/neu antibody-Rae-1 β fusion protein. (Months 7-12).

- a. Determine whether EMT6-HER2-Rae-1 β cells are rejected in mice.
- b. Investigate whether treatment of antibody-Rae-1 β fusion slow or regress tumor growth in mice bearing EMT6-HER2.
- c. Investigate anti-tumor activity of antibody-Rae-1 β fusion in EMT6-HER2 bearing mice, in which either of NK, CD4⁺, or CD8⁺ cells is depleted.
- d. To investigate whether NK cell-mediated tumor rejection promotes T cell immunity, mice that reject tumors will be rechallenged with either irrelevant tumors (CT26 or CT-26 HER2) or relevant tumors (EMT6, EMT6-HER2, or EMT6-HER2-Rae-1 β).

We did not complete the Aim III yet, but future efforts in the laboratory will continue to focus on testing efficacy of the fusion proteins in vivo in tumor models. This will include in vivo targeting and tumor challenge experiments using the Rae-1 β fusions using the CT26 and EMT6 breast cancer model to confirm the tumor regression experiment results and to determine the potential for engaging host immune responses. Finally we are actively pursuing the preclinical development of the Rae-1 β fusion due to the efficacy in CT26-HER2 and EMT6-HER2 models.

KEY RESEARCH ACCOMPLISHMENTS

1. Anti-HER2 IgG3-Rae-1 β fusion proteins of the expected molecular weight were secreted as the fully assembled H₂L₂ form.
2. Anti-HER2 IgG3-Rae-1 β fusion proteins bound to HER2⁺ on tumor cells and Rae-1 β fusion proteins recognized NKG2D on NK cells through Rae-1 β moiety.
3. Anti-HER2 IgG3-C_H3-Rae-1 β fusion protein promotes perforin expression in KY-2 in a dose-dependent manner.
4. The C_H3-Rae-1 β fusion markedly enhanced NK cell-mediated killing, while the H-Rae-1 β fusion protein exhibited only little improvement of tumor-directed cytotoxicity.
5. Both Rae-1 β moiety and Fc region of the fusion antibody appear to play important roles in tumor-directed cytotoxicity mediated by NK cells.

REPORTABLE OUTCOMES: Patent Application

This results has been presented at Department of Defense Breast Cancer Research Program Meeting, The 4th Era of Hope in Philadelphia, Pennsylvania, June 8-11, 2005. Symposium 34 and Poster (P39-12): Appendix 1.

A provisional patent has been filed on June, 2005 (Appendix 2). This provisional patent covers an anti-tumor antibody and a receptor ligand fused into a single protein for use as an anti-cancer therapeutic. A non-limiting example includes a fusion protein of anti-HER2 antibody fused to the NKG2D ligand Rae-1 β for a breast cancer therapeutic.

CONCLUSIONS

The purified Rae-1 β fusion proteins demonstrated ability to bind antigen on tumor cells and NKG2D on NK cells. The antibody-Rae-1 β fusion proteins showed increased cytotoxic activity directed against tumor targets.

The anti-HER2 antibody (Herceptin) is approved for the treatment of metastatic breast cancer. However, Herceptin is effective only in a small percent of patients whose tumors express HER2. Antibody-based cancer therapy is thought to lead to tumor destruction by activation of antibody dependent cytotoxicity (ADCC) and/or through direct effects on signaling by targeted receptors such as HER2. ADCC may be a major anti-cancer mechanism and it could be more effectively elicited in the presence of activated effector cells with increased cytolytic capacity derived through activation of a local innate immune response.

Furthermore we believe that an enhanced local innate response may lead to more efficient priming of an adaptive T cell mediated response. We have therefore used the targeting capabilities of an antibody to direct delivery of NKG2D ligand to the surface of tumor cells through the design and synthesis of an antibody-NKG2D ligand fusion protein. Local delivery and expression of NKG2D ligands on tumor cells effectively restores the balance of NK cell activation status in favor of stimulatory signals, provides a potent costimulatory signal to CD8⁺ T cells and can stimulate an effective anti-tumor response.

Antibody-NKG2D ligand fusion proteins could potentially be used to treat multiple different types of malignancies by substituting other tumor antigenic specificities in the antibody domain (e.g. EGFR, CD20, PSMA, etc). Once this concept is validated in mouse models, the murine NKG2G ligand in the antibody fusion molecule could be replaced with human NKG2D ligands such the MHC class I-related chain A and B, and UL16 binding proteins (ULBP1, ULBP2, ULBP3, ULBP4) for testing in humans. This invention refers specifically to the targeting of NKG2D ligands to tumor cells using an antibody-NKG2D ligand fusion protein targeted against a specific tumor associated antigen, in this specific case, the breast tumor antigen HER2.

REFERENCES

1. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. *Nat Immunol.* 2000;1:119-126.
2. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. *Immunol Rev.* 2002;188:9-21.
3. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. *Nature.* 2001;413:165-171.

4. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. *Proc Natl Acad Sci U S A*. 2001;98:11521-11526.
5. Shin SU, Friden P, Moran M, Olson T, Kang YS, Pardridge WM, Morrison SL. Transferrin-antibody fusion proteins are effective in brain targeting. *Proc Natl Acad Sci U S A*. 1995; 92(7):2820-4.

APPENDICES

Appendices 1 and 2 have been attached.

Appendix 1

Agenda

June 11, 2005

5:15-6:45 p.m.

CONCURRENT SYMPOSIA SESSIONS VI

Symposium 33 - Relationship between Biomarkers and Breast Cancer Pathology II Room 201A

Co-Chairs: Dennis C. Sgroi and Patricia Høgen

Human Tissue Kallikreins as Biomarkers for Breast, Ovarian, and Other Malignancies

Eleftherios Diamandis

Novel Image Analysis to Link Sub-Nuclear Distribution of Proteins with Cell Phenotype in Breast Neoplasia

David W. Knowles

Cancer Specific Proliferating Cell Nuclear Antigen as a Novel Diagnostic Marker for the Detection of Breast Cancer

Derek Hoelz

Sandwich Test ELISA with SCFV Antibodies: An Alternative to an All-Time Favorite

Nathalie Scholler

Symposium 34 - Antibodies: Innate versus Engineered Room 201B

Co-Chairs: Louis M. Weiner and Linda Vincent

Circulating Autoantibodies for Early Detection of Breast Cancer

Jean Latimer

Treatment of Breast Cancer with Antibodies against Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Death Receptors in Combination with Chemotherapy

Donald Buchsbaum

Inhibition of Breast Cancer Metastasis with Ligand Mimetic Antibodies from Cancer Patients

Brunhilde Felding-Habermann

Antibody-NKG2D Ligand (RAE-1BETA) Fusion Protein for Breast Cancer Therapy

Seung-Uon Shin

Cloning, Expression, and in Vitro Activity of a Pair of Truncated Bi-Specific Antibodies Targeting C1q to HER2

Xiaofeng Yang

Symposium 35 - Biological Function of High Risk Genes Room 201C

Co-Chairs: Andrew K. Godwin and Mary Jo Vazquez

Effects of Estrogen, Pregnancy, and Therapeutic Drugs on Mammary Tumor Formation in BRCA1-Conditional Mutant Mice

Chuxia Deng

Genome Wide Analysis of Allelic Imbalance in Tumor Epithelium and Stroma in BRCA1- and BRCA2-Related Breast Cancers

Frank Weber

BRCA1-Deficient Mammary Tumors Have Distinct Tumorigenesis Processes and Chemotherapy Response

Christopher R. Smith

BRCA1 Interacts with Highly Conserved Components of the Transcription Elongator Complex

Craig B. Bennett

BRCA1 Directly Modulates Gene Expression Required for Estrogen Biosynthesis: A Possible Mechanism of Tissue-Specific Tumor Suppression

Yanfeng Hu

Symposium 36 - DNA Damage and Repair II Room 204A

Co-Chairs: Zhenkun Lou and Karin D. Noss

Investigating the Genetic Interaction of the Homologous Recombination Proteins:

RAD51, BRCA2, and BLM

Teresa Marple

Involvement of Human MDC in ATM Function

Girdhar G. Sharma

Based on Selye's framework of Physiological Response to Stress and Lazarus and Folkman's Transactional Model of Stress, the specific aims of this study are to: (1) examine the association of objective and subjective breast cancer risk with immune responses; (2) examine the mediating role of psychological distress on the relationship between subjective breast cancer risk and immune responses; (3) determine the moderating role of dispositional optimism on the relationship between subjective breast cancer risk and psychological distress; and (4) assess the association between objective and subjective breast cancer risk in healthy women with (FH+) or without (FH-) family history of breast cancer in FDR.

For this cross-sectional study, a convenience sample of 94 healthy women (33 FH+, 61 FH-) completed self-report questionnaires for objective and subjective breast cancer risk, psychological distress and dispositional optimism and provided a blood sample. Objective breast cancer risk was calculated using the modified Gail model. NKCA and LAKCA were determined by a chromium-51 release cytotoxicity assay using K562 target cells.

Preliminary analyses indicated no association between objective and subjective breast cancer risk with NKCA and LAKCA (Aim 1), and no mediating role for psychological distress on the subjective breast cancer risk immune relationships (Aim 2). However, the moderating role of optimism on the relationship between subjective breast cancer and psychological distress was supported ($p = .013$) (Aim 3). In addition, objective and subjective breast cancer risk showed a positive significant correlation ($p = .003$) (Aim 4).

The results of these preliminary analyses indicate additional studies with larger samples of women having family history in FDR may help to advance the understanding of psychological-immune interactions in healthy women with varying degrees of breast cancer risk, and aid in developing better preventive strategies against breast cancer in the future.

The U.S. Army Medical Research and Materiel Command under W81XWH-04-1-0352 supported this work.

P39-12: ANTIBODY-NKG2D LIGAND (RAE-1BETA) FUSION PROTEIN FOR BREAST CANCER THERAPY

Seung-Uon Shin, Joseph D. Rosenblatt, Hyun-Mi Cho, and Khaled Tolba
University of Miami, Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL
E-mail: sshin@med.miami.edu

NKG2D ligands are inducible stress response molecules expressed on virally infected and transformed cells. NKG2D ligands activate the NKG2D receptor, a C type lectin-like receptor expressed on effector cells belonging to the innate and adaptive immune systems, and offer an effective link between innate and adaptive immunity necessary to mount potent anti-tumor response. Over expression of NKG2D ligands has led to tumor regression in multiple murine tumor models. In contrast to observations derived from murine tumor models, the wide spread expression of these ligands on many human cancers does not generate the anticipated tumor-specific innate or adaptive response seen in mouse tumor models. One explanation for this is the shedding of these ligands into the blood stream and down-regulation of the NKG2D receptor on effector cells. This has the effect of both reducing the surface expression of these ligands on tumor cells while blunting the effectiveness of the receptor itself. Over-expression of NKG2D ligands on tumor cells effectively restores the balance of NK cell activation status in favor of stimulatory signals, provides a potent costimulatory signal to CD8+ T cells and can stimulate an effective anti-tumor response. Since most women who succumb to breast cancer harbor metastatic disease, direct transduction strategies effectively employed in murine experimental models to express NKG2D ligands will not be practical.

We proposed the direct targeting of NKG2D ligands to tumor cells using an antibody-NKG2D ligand fusion protein targeted against the breast tumor antigen HER2. Using murine breast tumors designed to express the HER2 target antigen and the murine NKG2D ligand Rae-1beta, we constructed an anti-HER2 IgG3-CH3 Rae-1beta fusion protein by genetically fusing Rae-1beta at the 3' end of CH3 domain of anti-HER2 IgG3 antibody. We also constructed a retroviral vector of the full length of Rae-1beta (L-Rae-1beta-SDH) to generate a murine mammary tumor cell EMT6-HER2 expressing Rae-1beta. We have expressed a recombinant FLAG-tagged murine NKG2D soluble receptor for purposes of detection of Rae-1beta expression. We are now investigating the innate stimulatory properties of anti-HER2 antibody-Rae-1beta fusion protein in vitro and in vivo. In addition ability of the Rae-1beta fusion protein to slow tumor growth in an animal tumor model and/or lead to both an innate and adaptive response will be investigated.

The U.S. Army Medical Research and Materiel Command under W81XWH-04-1-0733 supported this work.

Appendix 2



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
60/695,114	06/29/2005		100	7230-23	1		

CONFIRMATION NO. 3406

30448
 AKERMAN SENTERFITT
 P.O. BOX 3188
 WEST PALM BEACH, FL 33402-3188

FILING RECEIPT



OC000000016726609

Date Mailed: 08/09/2005

Receipt is acknowledged of this provisional Patent Application. It will not be examined for patentability and will become abandoned not later than twelve months after its filing date. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

- ✓ Seung-Uon Shin, Miami, FL;
- ✓ Joseph D. Rosenblatt, Miami, FL;
- ✓ Khaled Tolba, Miami, FL;

Power of Attorney:

Nicholas Zachariades--56712

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

✓ ** SMALL ENTITY **

Title

- ✓ Antibody-NKG2D ligand fusion protein for cancer therapy

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no

effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).